Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,101–1,200 of 3,704
GLP ‐1 agonists for people living with HIV and obesity, is there a potential?
Zino, L., Tack, C. J., Richel, O., & Burger, D. M. (2023) · HIV Medicine · doi:10.1111/hiv.13521 · Cited by 14
“Additionally, tirzepa-tide, a combined GLP-1 and glucose-dependent insulino-tropic polypeptide agonist, seems to be even more powerful in inducing weight loss in obesity [44], and has been submitted for this indication as well.”
BackgroundYu, D., Shen, S., Zhang, J., & Wang, Q. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.008 · Cited by 12
Stumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Martelli, F., Bernini, V., Neviani, E., Vasconcelos, V. M., & Urbatzka, R. (2024) · Food & Function · doi:10.1039/d4fo00699b · Cited by 13
Detecting sarcopenia in obesity: emerging new approaches
Cappellari, G. G., Zanetti, M., Donini, L. M., & Barazzoni, R. (2024) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001062 · Cited by 24
Tirzepatide-related acute liver injury
Abdullah, I., El-Ghousain, H., & Alenezi, M. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004813 · Cited by 11
Singh, A., Singh, A. K., Singh, R., & Misra, A. (2025) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103212 · Cited by 13
Zakaria, H., Alshehhi, S., Caccelli, M., Ozkan, C., Kattan, J., Jafaar, Z., Laborte, R., Aleabova, S., Almarzooqi, N., Hashemi, A., et al. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100283 · Cited by 11
“Despite their efficacy and safety in previous trials like SUR-MOUNT [15,22], and STEP [14], there remains a necessity for a comprehensive examination of these medications from an independent perspective.”
Arslan, S. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103305 · Cited by 13
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment
Koceva, A., Janež, A., & Jensterle, M. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102038 · Cited by 17
Aimelet, V., & Holst, J. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70229 · Cited by 15
Crisafulli, S., Alkabbani, W., Paik, J. M., Bykov, K., Tavakkoli, A., Glynn, R. J., Htoo, P. T., Yu, E. W.-Y., Trifirò, G., Wexler, D. J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-01724 · Cited by 16
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Jebeile, H., Danielsen, Y. S., Sumithran, P., Lorien, S. J., Jardine, I. R., Baur, L. A., & Lister, N. B. (2025) · Obesity Reviews · doi:10.1111/obr.70049 · Cited by 15
“GLP-1 RA medications may induce mean weight loss of 4.6%–21% depending on medication type and dose [6, 34].”
InfluentialØstergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“%) after 72 weeks of treatment [80].”
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Genetically proxied impaired GIPR signaling and risk of 6 cancers
Rogers, M., Gill, D., Ahlqvist, E., Robinson, T., Mariosa, D., Johansson, M., Penha, R. C. C., Dossus, L., Gunter, M. J., Moreno, V. R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106848 · Cited by 11
“In our analyses, E354Q was associated with lower adult BMI levels which is not consistent with weight loss observed in clinical trials of GIPR agonists (alongside GLP1R agonists).(36,37) Interestingly, both GIPR agonists and antagonists have been shown to induce weight loss in preclinical settings.”
ResultCellular mechanism of diabetes remission by bariatric surgery
Ye, J., Hu, Y.-X., Wang, C., Lian, H., & Dong, Z. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.07.001 · Cited by 12
Promoting metabolic inefficiency for metabolic disease
Kazak, L. (2023) · iScience · doi:10.1016/j.isci.2023.107843 · Cited by 15
Shirin, H., Neeland, I. J., Ryan, D. H., de Luis, D. A., Lecube, A., MAGOS, Z., Kenan, Y., Amir, R., Cohen, D. L., & Johansen, O. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100094 · Cited by 10
“Some of the medications approved since 2000, when applied with a lifestyle intervention program, can also provide weight reduction of 10 % on average for most patients, and can improve quality of life [11 – 13].”
BackgroundAntza, C., Grassi, G. M., Weber, T., Persu, A., Jordan, J., Nilsson, P. M., Redón, J., Stabouli, S., Kreutz, R. H., & Kotsis, V. (2024) · Blood Pressure · doi:10.1080/08037051.2024.2317256 · Cited by 12
Xie, J., & Wang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001320 · Cited by 12
“The most frequent side effects were nausea [15 – 17] .”
BackgroundGlucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone, E. R., & Tan, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171219 · Cited by 11
“…of diabetes and obesity, culminating in the marketing of the dual GLP-1R/GIPR agonist tirze-patide which is clinically superior to the GLP-1 monoagonist semaglu-tide for glycemic improvement and weight loss in people with T2D [55], and is effective for treatment of obesity without T2D [56].”
BackgroundZhang, C., Yang, X., Wu, L., Liu, F., Dong, K., Guo, C., Gong, L., Dong, G., Shi, Y., Gu, Z., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00054 · Cited by 11
Reese‐Petersen, A. L., Nielsen, S. H., Sand, J. M. B., Schattenberg, J. M., Bugianesi, E., & Karsdal, M. A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15615 · Cited by 12
Obesity-Related Glomerulopathy: Epidemiology, Pathogenesis, and Current Treatments
Yang, X., Bayliss, G. P., & Zhuang, S. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-24-00011 · Cited by 12
“[100] Complementing these findings, [101] the farnesoid X receptor/G protein-coupled receptor 5 (FXR/TGR5) dual agonist has been shown to prevent mitochondrial dysfunction and oxidative stress, regulate multiple signaling pathways, and reduce proteinuria in ORG model mice.”
Samuels, J. M., Niswender, K. D., Roumie, C. L., Self, W., Holzman, M., Spann, M., Flynn, C. R., Ye, F., Irlmeier, R., Funk, L. M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15737 · Cited by 10
“11,12 13 – 16 GLP-1RA AOMs do not appear to lead to a heightened risk of AEs in patients who have previously undergone bariatric surgery.”
Legal, safety, and practical considerations of compounded injectable semaglutide
Spitery, A., Elder, M. J., Farhat, N., Mohammad, I., & Lobkovich, A. M. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1999 · Cited by 11
Al-Sabah, S. K., Al‐Khairi, I., Jamal, M. H., Qaddoumi, M. G., Al-Ajmi, F. A., Kumar, J., ABUKHALAF, N. A., Cherian, P., Madhu, D., Arefanian, H., et al. (2024) · Medical Principles and Practice · doi:10.1159/000540534 · Cited by 14
“Additionally, tirzepatide is reportedly effective in patients with moderate to severe obesity [33], making it a potential alternative for patients who are not eligible for bariatric surgery due to medical or other reasons.”
BackgroundMcVay, M. A., Moore, W. S., Wilkins, F. L., Jackson, J. R., & Robinson, M. D. (2024) · Obesity Science & Practice · doi:10.1002/osp4.783 · Cited by 10
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 13
Habel, N., Infeld, M. M., Lustgarten, D. L., & Meyer, M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.064 · Cited by 16
Park, M. Y., Tu, C., Pèrié, L., Verma, N., Serdan, T. D. A., Shamsi, F., Shapses, S. A., Heffron, S. P., Gamallo‐Lana, B., Mar, A. C., et al. (2024) · Endocrinology · doi:10.1210/endocr/bqae141 · Cited by 11
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
“Other reported effects were diarrhea and constipation (23% and 11.7%, respectively), all with mild-to-moderate severity, causing treatment discontinuation in a maximum of 7.1% of patients (161).”
InfluentialNew and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 15
“Tirzepatide has been shown to be effective in treating obesity 111 and obstructive sleep apnea 112 .”
Grosicki, G. J., Kim, J., Fielding, F., Jasinski, S. R., Chapman, C., von Hippel, W., & Holmes, K. E. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00809.2024 · Cited by 18
Kamrul-Hasan, A. B. M., Patra, S., Dutta, D., Nagendra, L., Muntahi-Reza, A., Borozan, S., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.101282 · Cited by 18
Grosicki, G. J., Thomas, J. G., Dhurandhar, N. V., Lofton, H. F., Heymsfield, S., & Jonnalagadda, S. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16151 · Cited by 12
Czernichow, S., Rassy, N., Carette, C., Shoung, N., Hu, F. B., & Rives‐Lange, C. (2025) · Obesity Reviews · doi:10.1111/obr.13890 · Cited by 11
“12,13 Due to substantial weight loss similar to the effects of bariatric surgery, 8 some NuSHs may influence the nutritional and functional status of people living with overweight and obesity, potentially placing them at risk of malnutrition.”
Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide
Louwagie, E. J., Diego, J. N., Farooqi, C. S., & Kamal, M. M. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf028 · Cited by 15
Hunter, T. M., Chinthammit, C., Ward, J. M., Cappell, K. A., Sedgley, R., Bonafede, M., Liao, B., & Hankosky, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16330 · Cited by 13
“23 The mean BMI of individuals initiating tirzepatide was in the upper end of class 1 obesity (overall cohort: 34.4 kg/m 2 ) or in class 2 obesity (AOM-eligible cohort: 35.8 kg/m 2 ).”
InfluentialGlucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
Turkistani, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1535134 · Cited by 10
Testosterone Therapy in Older Men: Present and Future Considerations
Yeap, B. B., Tran, C., Douglass, C. M., & McNeil, J. J. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01209-1 · Cited by 11
“Tirzepatide, a dual GLP-1 and GIP receptor agonist, resulted in 20.9% weight loss (versus 3.1% for placebo) after 72 weeks in middle-aged adults with obesity or overweight with one or more weight-related complications [64].”
InfluentialChen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Mustafa, Y. F. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100620 · Cited by 11
van Reekum, E. A., Darcy, M., Drage, J., Xu, J., Ng, K., Forestell, B., Santesso, N. A., Joundi, R. A., Wong, J. A., Doumouras, A. G., et al. (2025) · Obesity Reviews · doi:10.1111/obr.13968 · Cited by 14
“This suggests that anxiety symptom change could be related to the amount of weight reduction, since active nonsurgical interventions can substantially reduce weight, whereas passive groups like surgical wait-lists may not [20, 80].”
Overweight, Obesity and Diabetes: Global Trends and a Better Future?
McPake, B. (2025) · Health Systems & Reform · doi:10.1080/23288604.2025.2518797 · Cited by 16
“16 Trial data suggest sema-glutide to be associated with a mean 10.2% weight reduction 17 and tirzepatides with a mean 15.0% weight reduction 18 in patients without diabetes after one year, while both medications are well established as glucose lowering agents with increasing capacity to treat T2DM.”
InfluentialIncretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
“The mean change in body weight was 20.9% with 15 mg tirzepatide compared with 3.1% for the placebo group [101].”
InfluentialCurrent understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists
Feng, J., & Jin, T. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0026 · Cited by 17
“[75] When compared with Semaglutide, Tirzepatide treatment results 5% or greater weight loss with similar extent of gastrointestinal adverse events.”
Gupta, N., Babyak, A., Chorbajian, A., Tardio, V., Ballreich, J. M., & Dasgupta, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16627 · Cited by 11
“9,11,51 We capped utilities at 1.0 to avoid overestimation.”
InfluentialLópez-Jiménez, F. A., Cesare, M. D., Powis, J., Shrikhande, S. S., Adeoye, M., Codato, E., Zhou, B., Bixby, H., Evans, N. R., Lara-Breitinger, K. M., et al. (2025) · Global Heart · doi:10.5334/gh.1451 · Cited by 19
Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C. J., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J., Selzer, F., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03609 · Cited by 20
Sauter, E. R. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.01.029 · Cited by 13
Novel therapeutics in rare genetic obesities: A narrative review
Dubern, B., Faccioli, N., Poitou, C., & Clément, K. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106763 · Cited by 16
Should Prediabetes be Treated Pharmacologically?
Davidson, M. B. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01449-7 · Cited by 13
Kido, K., Carey, B., Caccamo, M. A., Bianco, C. M., & Sokos, G. G. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.09.011 · Cited by 12
Microvascular Dysfunction in Obesity-Hypertension
Do, T., Van, A., Ataei, A., Sharma, S., & Mohandas, R. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01272-2 · Cited by 11
“Tirzepatide, a dual glucose-dependent insuli-notropic polypeptide (GIP) and GLP-1 receptor agonist has even more efficacy in reducing weights than either agent alone [40].”
BackgroundAdvances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
Fisher, M. H., Ohmes, L. B., Yang, J. H., Le, E. L. H., Colakoğlu, S., French, M. M., Sıddıkoğlu, D., Um, G. T., Winocour, J. S., Higdon, K. K. “., et al. (2024) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2024.01.033 · Cited by 10
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Himmerich, H., & McElroy, S. L. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001869 · Cited by 12
Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 12
“In adults, it has been demonstrated to affect weight loss at 20.9% weight loss at the maximum dose of 15 mg compared to a 3.1% weight loss with placebo [52].”
InfluentialTargeting obesity for therapeutic intervention in heart failure patients
Sato, R., & von Haehling, S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2363395 · Cited by 10
“For further evidence of obesity-targeted treatment strategies in patients with HFpEF, sub-analyses of SELECT and clinical trials with incretin mimetics such as tirzepatide and retatrutide, which have shown more potent weight loss effects than GLP-1 analogues (Figure 2) [152,156], are warranted.”
BackgroundCurrent treatment landscape for obesity in Singapore
Lee, P. C., Lim, C. H., Asokkumar, R., & Chua, M. W. J. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-216 · Cited by 16
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 14
“9% with 5-, 10-, and 15-milligram doses, respectively, at 72 weeks in non-diabetic obese patients [51].”
BackgroundDiabetocardiology: a new subspecialty?
Braunwald, E. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad541 · Cited by 11
Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetitePreprint
McMorrow, H. E., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.18.585583 · Cited by 10
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
“18 For individuals with obesity-related diseases and complications, achieving ≥ 10% reduction in base-line body weight has consistently demonstrated improvements in these conditions.”
Influentialvon Haehling, S., Sato, R., Langer, H., Khan, M. S., Coats, A. J. S., Evans, W., Heymsfield, S., & Anker, S. D. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.70147 · Cited by 10
“Despite some functional gains observed in trials such as STEP-1 and SURMOUNT-1 [1, 9], particularly in patient-reported outcomes, it remains uncertain whether these improvements are clinically meaningful.”
InfluentialLütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0469 · Cited by 10
“Recently introduced as an anti-obesity medication, semaglutide 2.4 mg demonstrated a placebo-adjusted weight reduction of 12.4%, with almost one-third of individuals achieving a weight loss of 20% or more (21,22).”
InfluentialBrown, A., Mellor, D., Makaronidis, J., Shuttlewood, E., Miras, A. D., & Pournaras, D. J. (2024) · Nutrition Bulletin · doi:10.1111/nbu.12700 · Cited by 9
Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
Wu, C. C., Cengiz, A., & Lawley, S. D. (2025) · Obesity · doi:10.1002/oby.24302 · Cited by 9
“Black markers show weight loss data from Jastreboff et al. [7] (semaglutide in panel A) and Wilding et al. [6] (tirzepatide in other three panels) for the placebo (square markers) and the drug (circle markers Note : The final four rows indicate how the steady-state weight loss for various…”
Richards, R., Lunt, W., Whitman, M., Spaltro, G., & Hall, R. (2025) · JMIR Formative Research · doi:10.2196/81912 · Cited by 15
“The side effect profiles for both semaglutide and tirzepatide were consistent with clinical trial data, with constipation, nausea, and fatigue being most common [10,29,40].”
InfluentialChen, N., Zhang, M., Shi, B., Luo, X., Huang, R., Luo, Z., He, J., Xue, S., Li, N., Ling, Z., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.09.002 · Cited by 12
“Moreover, SURMOUNT-1 [29] and SURMOUNT-CN [30] programs demonstrated the efficacy and safety of TZP for weight loss in obese (non-diabetic) patients.”
From needles to pills: oral GLP-1 therapy enters the obesity arena
Santulli, G. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00245-5 · Cited by 13
“” Yet, the absence of direct comparison — particularly against injectable semaglutide (50 mg) [3] or tirzepatide [4, 5] (Table 1) — makes such judgments somehow premature.”
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
“Furthermore, tirzepatide, a novel dual GIP/GLP-1 RA, has shown remarkable efficacy in the management of obesity, in delaying the onset of T2DM among individuals with prediabetes, in reducing HbA1c levels, and improving obesity-related obstructive sleep apnea (OSA) [179,180].”
Optimizing GLP-1 therapies for obesity and diabetes management
Noronha, J. C., Gaal, L. F. V., Neeland, I. J., Fitch, A., Pfeiffer, A. F. H., Chiavaroli, L., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100222 · Cited by 21
“At week 72, mean weight loss was (cid:0) 15.0 % (5 mg tirzepatide), (cid:0) 19.5 % (10 mg tirzepatide), and (cid:0) 20.9 % (15 mg tirzepatide) vs (cid:0) 3.1 % with placebo [5].”
InfluentialKaiser, M., Parikh, M. A., Turitto, G., Frishman, W. H., & Peterson, S. J. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001113 · Cited by 14
Chrysavgis, L., Mourelatou, N. G., Koloutsou, M. E., Rozani, S., & Cholongitas, Ε. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412130 · Cited by 16
“Comparative studies are needed to define how newer dual and triple agonists affect lean mass relative to traditional GLP-1 monotherapy, given their ability to induce substantially greater weight loss [125,139].”
InfluentialWadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
“Trial designs and results for the 72-week SURMOUNT-1, SURMOUNT-2, and SURMOUNT-3 studies have been published [3, 8, 30].”
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 16
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Hsu, A. H.-C., Ramirez, P. T., Chang, Y.-H., Chiang, Y. C., Santía, M. C., Meschini, T., Mateo-Kubach, P., Suri, A., & Kamat, A. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.013 · Cited by 13
Liu, M., Xu, X., Chen, X., Guo, Y., Zhang, S., Lin, Y., Zhou, H., Li, M., Xie, P., Xia, W., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad165 · Cited by 9
Self-citationManagement of hyperglycaemia in people with obesity
Mourougavelou, V., & Chowdhury, T. A. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0135 · Cited by 11
Ceriello, A., Rodbard, H. W., Battelino, T., Brosius, F. C., Cosentino, F., Green, J., Ji, L., Kellerer, M., Koob, S., Kosiborod, M., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01993-3 · Cited by 12
A closer look at weight loss interventions in primary care: a systematic review and meta-analysis
Perreault, L., Kramer, E. S., Smith, P. C., Schmidt, D. W., & Argyropoulos, C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1204849 · Cited by 14
“12 highly effective pharmacotherapy (29, 30) may make patient weight loss of 15-22% achievable.”
BackgroundKnihs, V. M., & Filippin-Monteiro, F. B. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102956 · Cited by 9
Medical Weight Management Considerations in Plastic Surgery
Paranzino, A. B., Vieira, B. L., Apovian, C. M., & Agarwal, S. (2024) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000011445 · Cited by 11
“31 Mounjaro received FDA approval for type 2 diabetes treatment in May of 2022, and tirz-epatide has been fast-tracked by the FDA for obesity treatment.”
Singh, A., & Nissen, S. E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0122 · Cited by 11
“32 The eagerly awaited SURPASS-CVOT and SURMOUNT-MMO trials are investigating the effects of tirzepatide on cardiovascular outcomes in patients with and without diabetes.”
Fuller, T., Newberry, Z., Nasir, M., & Tondt, J. (2024) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2024.04.007 · Cited by 9
Larsen, A. T., Mohamed, K. E., Melander, S. A., Karsdal, M. A., & Henriksen, K. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00092.2024 · Cited by 12
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?
Kaplan, J. M., Zaman, A., & Abushamat, L. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02097-4 · Cited by 12
“…approved a dual GLP-1 and GIP receptor agonist, tirzepatide, for the management of obesity after it was demonstrated to lead to a mean of 20.9% total body weight loss; 90.1% of study participants lost at least 10% of their total body weight after seventy-two weeks of treatment on maximum dose [52].”
InfluentialO’Donnell, C., Ryan, O. K., Hogan, A. E., Killick, D., Crilly, S., Dodd, J. D., Murphy, D. J., Ryan, S., & O'Shea, D. B. (2024) · Obesity · doi:10.1002/oby.24126 · Cited by 11
“These medications are delivering significantly better weight loss outcomes than other pharmacotherapies, with recent studies having shown body weight reduction of up to 30% [2, 3].”
Hirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
“Numerous studies have shown that GLP-1RA medications improve glycaemic control with lower hypoglycaemia risk 38,39 and reduce body weight 8 – 11, 39, 40 compared with insulin therapy.”
Kelkar, R., Barve, N., Kelkar, R., Kharel, S., Khanapurkar, S., & Yadav, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1453297 · Cited by 10
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
Harej, A., Pilipović, K., Belančić, A., Juretić, L., Vitezić, D., & Mršić‐Pelčić, J. (2024) · Pharmaceuticals · doi:10.3390/ph17101313 · Cited by 11
“They demonstrated a similar safety profile as in diabetes trials and a mean weight loss (after 56–72 weeks) of − 6.4%, − 15.8%, and − 22.5%, respectively [52–54].”
BackgroundInfluentialDoes Incretin Agonism Have Sustainable Efficacy?
Janket, S., Chatanaka, M. K., Sohaei, D., Tamimi, F., Meurman, J. H., & Diamandis, E. P. (2024) · Cells · doi:10.3390/cells13221842 · Cited by 11
Grandhi, N., Liu, L., Wang, M., Thomas, T. S., Schoen, M. W., Sanfilippo, K. M., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae095 · Cited by 13
“Recently, GLP-1 receptor agonists have gained widespread use because of their weight-loss effects (29-31).”
Holt, R., Holt, J., Jorsal, M. J., Sandsdal, R. M., Jensen, S. B. K., Byberg, S., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae775 · Cited by 13
Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion
Xu, Y., Michalowski, C. B., Koehler, J. A., Darwish, T., Guccio, N., Alcaino, C., Domingues, I., Zhang, W., Marotti, V., Hul, M. V., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq9909 · Cited by 10
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.